In an exciting collaboration aimed at advancing treatments for rare diseases, the Abu Dhabi Health Authority has joined forces with GemaBio Therapeutics. This partnership highlights the commitment of both entities to develop innovative gene therapies that will ultimately benefit patients across the Middle East and North Africa. As the need for effective health solutions grows, this alliance is set to pave the way for groundbreaking advancements in gene therapy.
Details of the Partnership
The Abu Dhabi Health Authority and M42, a global health-focused company harnessing artificial intelligence, have announced this strategic partnership with GemaBio Therapeutics at the World Biotech Innovation Conference 2025 held in Boston, USA. This important collaboration brings together top leadership from GemaBio and esteemed figures from Abu Dhabi’s healthcare and life sciences sectors.
Collaborative Goals
The partnership aims to explore opportunities to establish specialized research and manufacturing centers within the academic health institutions in Abu Dhabi. This initiative will enable patients in the Middle East and North Africa to access cutting-edge clinical trials and approved gene therapies. An ambitious clinical trial will initially focus on developing gene therapies for children suffering from Spinal Muscular Atrophy Type 1 (SMA1), marking a significant global milestone in expanding access to life-saving treatments.
Statements from Leadership
Dr. Mohammed Al Amiri, Acting Director of Genomics and Biobank Management at the Abu Dhabi Health Authority, emphasized the significance of this partnership, stating, “Our collaboration with GemaBio is a vital step that solidifies Abu Dhabi’s leading global position in developing gene therapies for rare diseases, leveraging the capabilities of the Emirati Genome Program.” This sentiment reflects the collective vision of both parties to enhance patient outcomes through innovative health solutions.
The partnership between the Abu Dhabi Health Authority and GemaBio Therapeutics promises to be a transformative force in the field of rare disease treatment, showcasing the potential of gene therapy in addressing unmet medical needs in the region.